The safety and immunogenicity of heat-killed Mycobacterium vaccae vaccine were investigated in a pilot study assessing the feasibility of immunization to prevent mycobacterial disease in patients with human immunodeficiency virus (HIV) infection. Fifteen (seven healthy and eight HIV-positive subjects) received five doses of M. vaccae vaccine. Lymphocyte proliferation assays (LPAs) were performed using Mycobacterium avium sensitin (MAS) and M. vaccae sonicate (MVS). Vaccine was well tolerated in all 15 subjects with minimal induration at the vaccine site. LPAs for four of seven healthy vaccinees were positive for MAS after immunization. Median responses to MAS and MVS that were determined by LPAs were consistently higher for the eight HIV-positive vaccinees than for the seven healthy controls. A five-dose series of M. vaccae vaccine is safe for both healthy and HIV-positive subjects and deserves further evaluation as a vaccine to prevent HIV-associated mycobacterial disease.
Mycobacterium vaccae vaccine is an experimental heatlocal and systemic side effects. Controls underwent in vitro killed vaccine prepared from an environmental Mycobacterium studies 3 months after MAS skin testing. that has been shown to protect against tuberculosis in a mouse HIV-positive subjects. Eight of the original 11 HIV-posimodel [1, 2] . We have conducted phase 1 studies with tive vaccine recipients with baseline CD4 cell counts of M. vaccae vaccine that assessed its safety and immunogenicity ú300/mm 3 who completed a three-dose trial [4] volunteered as a possible vaccine to prevent mycobacterial infections in to receive two additional doses of M. vaccae vaccine. HIV-HIV-positive adults and children [3, 4] . In the present pilot positive controls were seven unvaccinated subjects with CD4 study, we administered two additional doses of M. vaccae vaccell counts of ú300/mm 3 . Vaccinees received five intradermal cine to healthy adults and HIV-positive adults who participated doses of M. vaccae vaccine at 0, 2, 4, 25, and 26 months. HIVin our three-dose phase 1 studies and compared their cellular positive controls did not receive vaccine but underwent in vitro immune responses to mycobacteria with those in unimmunized studies on the same days before dose 4 for the vaccinees and controls.
repeated in vitro studies plus skin tests on the same days after dose 5 for the vaccinees. Blood samples for in vitro studies were always obtained before skin tests were administered, and Methods results of skin tests were read at 48 or 72 hours. Vaccinees Healthy subjects. Seven of the original nine healthy adult were contacted by telephone 2 and 14 days after immunization subjects who completed a three-dose trial [3] volunteered to to assess local and systemic side effects of the vaccine. receive two additional doses of M. vaccae vaccine (lot MV001,
Antigens. Subjects were skin tested with 0. (LPAs) . For healthy vaccine subjects and controls, specimens were processed and separated as described previously [3] . For HIV-positive vaccine subjects mine, 25 mM HEPES buffer, 50 mg of gentamicin sulfate/mL, (table 1) . These four vaccinees included three subjects (nos. 4, 7, and 8) with baseline skin test reactions to MAS of §5 mm and 5 mg polymyxin B/mL (complete RPMI.) PBMC suspensions were then diluted to 1 1 10 6 cells/mL in complete RPMI. and one subject (no. 9) with conversion of a baseline skin test reaction to MAS of 0 mm to 8 mm after dose 5. All six subjects For healthy vaccine subjects and controls, LPAs were performed as described previously [3] . For HIV-positive vaccine with PPD skin test reactions of 0 mm at baseline remained PPD-negative. subjects and controls, LPAs were performed by adding 100 mL of PBMC suspension to wells containing 100 mL of mycobacteLPAs detected responses to MAS (stimulation index, §3.0) either before dose 4 (i.e., after three doses) or after dose 5 in rial antigen solutions in 96-well culture plates. Local reactions were minor, and systemic side effects were uncommon and self-limited. Conversions of PPD skin tests did Vaccine side effects. For healthy subjects, the median vaccine site induration at 2 days was 8 mm (range, 6 -11 mm) not occur, and there was no adverse effect on HIV load. LPAs positive for MAS (a culture-filtrate of M. avium antiafter dose 4 and 7 mm (range, 4 -13 mm) after dose 5. Three subjects reported a sore arm after dose 4, and one reported a gens) were observed for both healthy and HIV-positive subjects. Because MAS skin testing was performed four times sore arm after dose 5. One subject reported fever and another reported headache, nausea, and night sweats after dose 4; one before dose 4 for healthy subjects and two times before dose 4 for HIV-positive subjects, we cannot exclude the possibility subject reported fever after dose 5.
Erythema at the vaccine site at 2 days was reported by four that repeated MAS skin testing several months before in vitro studies may have had an effect on lymphocyte proliferation HIV-positive subjects after dose 4 and by two HIV-positive subjects after dose 5. No HIV-positive subject reported sysresponses to MAS, especially in healthy subjects with positive baseline skin test reactions to MAS. temic side effects after either dose. The median log change between individual viral loads before dose 4 and after dose 5 Median LPA responses to the vaccine antigen (MVS), however, were also higher for the HIV-positive vaccinees than for was 0.0 for the vaccinees and /0.5 for the controls (P Å .24). The median change in individual CD4 cell counts before dose the HIV-positive controls. These differences did not achieve statistical significance in this small trial, but the consistently 4 and after dose 5 was 096/mm 3 for six vaccine recipients and /24/mm 3 for four controls (P Å .14). higher values for the vaccinees suggest a biological effect. Responses were not always observed during both testing interOf the 10 original healthy subjects, two were lost to followup, and the remaining eight were free from vaccine-related side vals for HIV-positive subjects, a finding that may be due to known variations in lymphocyte function during the course of effects when seen in January 1997, 31 months after the first dose of vaccine. Of the 12 original HIV-positive subjects, 10 HIV infection. Responses to MVS in this study occurred less frequently than did those in a similar trial involving HIVwere alive and well in December 1997, 28 months after the first dose of vaccine; none had vaccine-related side effects.
positive subjects in Zambia who had more prior exposure to mycobacteria (C. F. von Reyn, unpublished data). LPA results and skin test responses. LPAs detected responses to MAS in one of seven healthy vaccinees before dose Animal models and epidemiological studies of humans suggest that infection with nontuberculous mycobacteria protects 4 vs. four of seven healthy vaccinees after dose 5 (P Å .09) / 9c5c$$de17
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